相关实验视频
Updated: Jan 17, 2026
11:53
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
56.2K
癌症患者的死亡率在重症监护的感染性休克:系统性审查和元分析
María Fernanda García-Aguilera1,2,3,4, Yunqi Yu-Liu5, Harold Alexander-León4,6
1Facultad de Ciencias Médicas, Universidad Central de Ecuador Facultad de Ciencias Médicas, Quito, Ecuador.
Journal of intensive care medicine
|September 15, 2025
概括
尽管在癌症治疗和败血症管理方面取得了进展,但患有败血症的癌症患者的死亡率仍然很高,为58%. 在重症监护室出院后,生存率显著下降,这凸显了治疗这一脆弱人群的持续挑战.
科学领域:
- 在瘤学瘤学.
- 临界护理医学 临界护理医学
- 传染性疾病 传染性疾病
背景情况:
- 癌症患者常常有免疫系统受损,增加了对诸如败血症等严重感染的敏感性.
- 尽管癌症疗法和败血症治疗方案取得了进展,但危急癌症患者的发病率正在上升.
- 虽然癌症患者的感染性休克生存率有所改善,但整体死亡率仍然令人担忧地高.
研究的目的:
- 系统地审查和分析癌症患者的败血症休克死亡率.
- 根据时间段,地理位置和护理环境来确定死亡率的变化.
主要方法:
- 在主要的医学数据库 (Medline,EMBASE,SCOPUS,Web of Science,BIREME-BVS) 中进行了全面的系统搜索.
- 包括的研究重点关注18岁以上的癌症患者经历败血症休克的死亡率.
- 方法质量和偏差风险使用MInCir-预报量表和Joanna Briggs Institute检查清单进行评估.
主要成果:
- 性休克的癌症患者的整体死亡率为58% (95%CI:54-63).
- 死亡率显示区域差异,北美报告最高的64% (95%CI:48-78).
- 随着时间的推移,重症监护室出院后的死亡率增加了69% (95% CI:58-80) 在180天后.
结论:
- 尽管医学取得了进步,但败血栓休克仍然是癌症患者死亡的主要原因.
- 在最近的时间段中,死亡率似乎没有显著下降.
- 需要改进管理策略,特别是在这种人群中改善重症监护病房后的存活率.
相关概念视频
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:30Pneumonia III: Complications and Assessment
788
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
788